PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.27%
Negative G&A growth (overhead reduction) needs verification. Benjamin Graham would examine impact on operations.
No Data
No Data available this quarter, please select a different quarter.
264.51%
Other expenses growth above 20% signals concerning cost expansion. Seth Klarman would scrutinize unusual items.
3.15%
Operating expenses growth 0-5% reflects moderate increase. Benjamin Graham would check revenue alignment.
3.15%
Total costs growth 3-5% suggests significant expansion. Howard Marks would investigate necessity.
-0.34%
Negative interest expense growth needs verification. Benjamin Graham would examine debt reduction strategy.
-75.00%
Negative D&A growth needs verification. Benjamin Graham would examine asset reduction strategy.
15.50%
EBITDA growth above 15% demonstrates exceptional operating performance. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
16.24%
Operating income growth above 15% demonstrates exceptional core profitability. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
-3.90%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.90%
Tax expense growth 0-10% reflects moderate increase. Benjamin Graham would investigate drivers.
12.65%
Net income growth 12-15% shows strong earnings momentum. Peter Lynch would examine growth drivers.
No Data
No Data available this quarter, please select a different quarter.
12.55%
EPS growth 12-15% shows strong earnings momentum. Peter Lynch would examine growth drivers.
12.55%
Diluted EPS growth 12-15% shows strong earnings power. Peter Lynch would examine growth drivers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.